241 related articles for article (PubMed ID: 17468115)
1. Acquired resistance to echinocandins in Candida albicans: case report and review.
Baixench MT; Aoun N; Desnos-Ollivier M; Garcia-Hermoso D; Bretagne S; Ramires S; Piketty C; Dannaoui E
J Antimicrob Chemother; 2007 Jun; 59(6):1076-83. PubMed ID: 17468115
[TBL] [Abstract][Full Text] [Related]
2. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
3. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
4. [Antifungal susceptibility for Candida albicans isolated from AIDS patients with oropharyngeal and esophageal candidiasis: experience with Etest].
Tapia C; González P; Pereira A; Pérez J; Noriega LM; Palavecino E
Rev Med Chil; 2003 May; 131(5):515-9. PubMed ID: 12879812
[TBL] [Abstract][Full Text] [Related]
5. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis.
Hernandez S; López-Ribot JL; Najvar LK; McCarthy DI; Bocanegra R; Graybill JR
Antimicrob Agents Chemother; 2004 Apr; 48(4):1382-3. PubMed ID: 15047549
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echinocandins on Aspergillus fumigatus and Candida albicans.
Manavathu EK; Ramesh MS; Baskaran I; Ganesan LT; Chandrasekar PH
J Antimicrob Chemother; 2004 Feb; 53(2):386-9. PubMed ID: 14729762
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.
de Wet N; Llanos-Cuentas A; Suleiman J; Baraldi E; Krantz EF; Della Negra M; Diekmann-Berndt H
Clin Infect Dis; 2004 Sep; 39(6):842-9. PubMed ID: 15472817
[TBL] [Abstract][Full Text] [Related]
8. Micafungin.
Carver PL
Ann Pharmacother; 2004 Oct; 38(10):1707-21. PubMed ID: 15340133
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with caspofungin and fluconazole for Candida albicans infection.
Barchiesi F; Spreghini E; Baldassarri I; Marigliano A; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2004 Oct; 48(10):4056-8. PubMed ID: 15388480
[TBL] [Abstract][Full Text] [Related]
10. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of caspofungin (MK-0991) against Candida albicans clinical isolates displaying different mechanisms of azole resistance.
Bachmann SP; Patterson TF; López-Ribot JL
J Clin Microbiol; 2002 Jun; 40(6):2228-30. PubMed ID: 12037093
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice.
Maesaki S; Hossain MA; Miyazaki Y; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 2000 Jun; 44(6):1728-30. PubMed ID: 10817741
[TBL] [Abstract][Full Text] [Related]
13. Molecular characterization of fluconazole resistance in a case of Candida albicans ocular infection.
Pancholi P; Park S; Perlin D; Kubin C; Della-Latta P
J Clin Microbiol; 2004 Dec; 42(12):5938-9. PubMed ID: 15583347
[TBL] [Abstract][Full Text] [Related]
14. Clinical resistance of recurrent Candida albicans vulvovaginitis to fluconazole in the presence and absence of in vitro resistance.
MacNeill C; Weisz J; Carey JC
J Reprod Med; 2003 Feb; 48(2):63-8. PubMed ID: 12621787
[TBL] [Abstract][Full Text] [Related]
15. [In vitro activity of caspofungin against fluconazole-resistant Candida isolates from patients with HIV infection].
Ortiz de la Tabla-Ducasse V; Masiá-Canuto M; Martín-González C; Gutiérrez-Rodero F
Enferm Infecc Microbiol Clin; 2004; 22(6):328-31. PubMed ID: 15228899
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of fluconazole resistance mechanisms in candida albicans clinical isolates from HIV-infected patients in Brazil.
Goldman GH; da Silva Ferreira ME; dos Reis Marques E; Savoldi M; Perlin D; Park S; Godoy Martinez PC; Goldman MH; Colombo AL
Diagn Microbiol Infect Dis; 2004 Sep; 50(1):25-32. PubMed ID: 15380275
[TBL] [Abstract][Full Text] [Related]
17. [Azole resistance in Candida albicans].
Perea S
Rev Esp Quimioter; 2000 Sep; 13(3):314-7. PubMed ID: 11086283
[TBL] [Abstract][Full Text] [Related]
18. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
Chen J; Li H; Li R; Bu D; Wan Z
J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
[TBL] [Abstract][Full Text] [Related]
19. Rapid flow-cytometric susceptibility testing of Candida species.
Rudensky B; Broidie E; Yinnon AM; Weitzman T; Paz E; Keller N; Raveh D
J Antimicrob Chemother; 2005 Jan; 55(1):106-9. PubMed ID: 15546969
[TBL] [Abstract][Full Text] [Related]
20. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
